Cyril Goizet

Cyril Goizet

Auto-generated profile, based on publicly available information

Cyril Goizet

Service de Génétique Médicale, GH Pellegrin, CHU de Bordeaux, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2007 in neurogenetics
Verified
Journal Article
Closed access
PDF file
CDChristel Depienne
Christel Depienne
EFEstelle Fedirko
Estelle Fedirko
JFJean-Marc Faucheux
Jean-Marc Faucheux
SFSylvie Forlani
Sylvie Forlani
BBBernard Bricka
Bernard Bricka
ABAlexis Brice
Alexis Brice

21 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CPClaire Pujol
Claire Pujol
ALAnne Legrand
Anne Legrand
LPLivia Parodi
Livia Parodi
PTPriscilla Thomas
Priscilla Thomas
FMFanny MOCHEL
Fanny MOCHEL
GSGiovanni Stevanin
Giovanni Stevanin
Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders. Understanding of their pathogenic mechanisms remains sparse, and therapeutic options are lacking. We characterized a mouse model lacking the Cyp2u1 gene, loss of which is known to be involved in a complex form of these diseases in humans. We showed that this model partially recapitulated the clinical and biochemical phenotypes of patients. Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far. We also confirmed brain calcifications as a potential biomarker in patients. Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues.

27 December 2024 in European Journal of Neurology
Verified
Journal Article
Open access
MDManon Degoutin
Manon Degoutin
CAChloe Angelini
Chloe Angelini
CBClaire Bar
Claire Bar
WKWahiba Amer El Khedoud
Wahiba Amer El Khedoud
CBChristine Barnerias
Christine Barnerias
CGCyril Goizet
Cyril Goizet
Purpose: Heterozygous pathogenic variants in SPAST are known to cause Hereditary Spastic Paraplegia 4 (SPG4), the most common form of HSP, characterized by progressive bilateral lower limbs spasticity with frequent sphincter disorders. However, there are very few descriptions in the literature of patients carrying biallelic variants in SPAST.Methods: Targeted Sanger sequencing, panel sequencing and exome sequencing were used to identify the genetic causes in 9 patients from 6 unrelated families with symptoms of HSP or infantile neurodegenerative disorder.Results: We describe 5 patients with pure HSP with a variable age of onset, mostly in infancy, and 4 patients with profound intellectual disability and progressively worsening tetrapyramidal syndrome. The patients' parents, heterozygous carriers of pathogenic SPAST variants, included both asymptomatic carriers and patients with classic forms of SPG4.Conclusion: Biallelic variants of SPAST may explain cases of hereditary spastic paraplegia with autosomal recessive inheritance. Furthermore, some biallelic variants may also cause psychomotor regression with an infantile neurodegenerative disorder, associated with a tetrapyramidal syndrome, a new phenotype associated with the SPAST gene.

1 July 2015 in Archives de Pédiatrie
Verified
Journal Article
Closed access
ABAurélia Bertholet-Thomas
Aurélia Bertholet-Thomas
BLB. Llanas
B. Llanas
ASAude Servais
Aude Servais
NBN. Bendelac
N. Bendelac
CGC. Goizet
C. Goizet
SDS. Decramer
S. Decramer

24 November 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
CGClaire Guissart
Claire Guissart
ECElisa De la Cruz
Elisa De la Cruz
OFOlivier Flabeau
Olivier Flabeau
AGAude-Marie Grapperon
Aude-Marie Grapperon
GCGiovanni Corazza
Giovanni Corazza
KMKevin Mouzat
Kevin Mouzat
We performed molecular analysis of 1130 patients with ALS, with 50 of them meeting the criteria for juvenile ALS. Plasma lipid profile of patients with SPTLC1 mutation were analysed using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and tandem mass spectrometry (MS/MS).

23 June 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
FRFlorence Riccardi
Florence Riccardi
BDBeatrice Desnous
Beatrice Desnous
EBEmilie Borloz
Emilie Borloz
ALAnne Lepine
Anne Lepine
CLCaroline Lacoste
Caroline Lacoste
MMMathieu Milh
Mathieu Milh
Background and ObjectivesDevelopmental and epileptic encephalopathies (DEEs) with early burst-suppression EEG (EIDEE-BS) are among the most severe neonatal epileptic syndromes, typically presenting...